Xencor Inc
NASDAQ:XNCR

Watchlist Manager
Xencor Inc Logo
Xencor Inc
NASDAQ:XNCR
Watchlist
Price: 25.01 USD 3.78% Market Closed
Market Cap: 1.8B USD
Have any thoughts about
Xencor Inc?
Write Note

Intrinsic Value

XNCR's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one XNCR stock under the Base Case scenario is 16.41 USD. Compared to the current market price of 25.01 USD, Xencor Inc is Overvalued by 34%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

XNCR Intrinsic Value
16.41 USD
Overvaluation 34%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Xencor Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for XNCR cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about XNCR?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Xencor Inc

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Xencor Inc

Provide an overview of the primary business activities
of Xencor Inc.

What unique competitive advantages
does Xencor Inc hold over its rivals?

What risks and challenges
does Xencor Inc face in the near future?

Has there been any significant insider trading activity
in Xencor Inc recently?

Summarize the latest earnings call
of Xencor Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Xencor Inc.

Provide P/S
for Xencor Inc.

Provide P/E
for Xencor Inc.

Provide P/OCF
for Xencor Inc.

Provide P/FCFE
for Xencor Inc.

Provide P/B
for Xencor Inc.

Provide EV/S
for Xencor Inc.

Provide EV/GP
for Xencor Inc.

Provide EV/EBITDA
for Xencor Inc.

Provide EV/EBIT
for Xencor Inc.

Provide EV/OCF
for Xencor Inc.

Provide EV/FCFF
for Xencor Inc.

Provide EV/IC
for Xencor Inc.

Show me price targets
for Xencor Inc made by professional analysts.

What are the Revenue projections
for Xencor Inc?

How accurate were the past Revenue estimates
for Xencor Inc?

What are the Net Income projections
for Xencor Inc?

How accurate were the past Net Income estimates
for Xencor Inc?

What are the EPS projections
for Xencor Inc?

How accurate were the past EPS estimates
for Xencor Inc?

What are the EBIT projections
for Xencor Inc?

How accurate were the past EBIT estimates
for Xencor Inc?

Compare the revenue forecasts
for Xencor Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Xencor Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Xencor Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Xencor Inc compared to its peers.

Compare the P/E ratios
of Xencor Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Xencor Inc with its peers.

Analyze the financial leverage
of Xencor Inc compared to its main competitors.

Show all profitability ratios
for Xencor Inc.

Provide ROE
for Xencor Inc.

Provide ROA
for Xencor Inc.

Provide ROIC
for Xencor Inc.

Provide ROCE
for Xencor Inc.

Provide Gross Margin
for Xencor Inc.

Provide Operating Margin
for Xencor Inc.

Provide Net Margin
for Xencor Inc.

Provide FCF Margin
for Xencor Inc.

Show all solvency ratios
for Xencor Inc.

Provide D/E Ratio
for Xencor Inc.

Provide D/A Ratio
for Xencor Inc.

Provide Interest Coverage Ratio
for Xencor Inc.

Provide Altman Z-Score Ratio
for Xencor Inc.

Provide Quick Ratio
for Xencor Inc.

Provide Current Ratio
for Xencor Inc.

Provide Cash Ratio
for Xencor Inc.

What is the historical Revenue growth
over the last 5 years for Xencor Inc?

What is the historical Net Income growth
over the last 5 years for Xencor Inc?

What is the current Free Cash Flow
of Xencor Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Xencor Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Xencor Inc

Current Assets 573.3m
Cash & Short-Term Investments 543m
Receivables 10.2m
Other Current Assets 20.1m
Non-Current Assets 410.3m
Long-Term Investments 290.3m
PP&E 101.2m
Intangibles 17.9m
Other Non-Current Assets 883k
Current Liabilities 92m
Accounts Payable 18.8m
Accrued Liabilities 27.6m
Other Current Liabilities 45.6m
Non-Current Liabilities 167.8m
Long-Term Debt 10.2m
Other Non-Current Liabilities 157.7m
Efficiency

Earnings Waterfall
Xencor Inc

Revenue
85.2m USD
Operating Expenses
-302.6m USD
Operating Income
-217.5m USD
Other Expenses
19.2m USD
Net Income
-198.2m USD

Free Cash Flow Analysis
Xencor Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Earnings Calls

In 2023, Xencor emphasized its T-cell engagers, particularly vudalimab for prostate and lung cancer, reducing investment in cytokine candidates. Its XmAb platform was validated by Amgen's data, and collaborative CD28 bispecific trials began with J&J, underscoring strong partnerships. A strategic royalty monetization significantly enhanced its balance sheet, resulting in a robust $697 million ending cash balance. Xencor now anticipates a financial runway extending into 2027.

What is Earnings Call?
Fundamental Scores

XNCR Profitability Score
Profitability Due Diligence

Xencor Inc's profitability score is 13/100. The higher the profitability score, the more profitable the company is.

Negative Revenue Growth Forecast
Negative 1-Year Revenue Growth
Declining ROE
Declining ROIC
13/100
Profitability
Score

Xencor Inc's profitability score is 13/100. The higher the profitability score, the more profitable the company is.

XNCR Solvency Score
Solvency Due Diligence

Xencor Inc's solvency score is 73/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Low D/E
Long-Term Solvency
73/100
Solvency
Score

Xencor Inc's solvency score is 73/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

XNCR Price Targets Summary
Xencor Inc

Wall Street analysts forecast XNCR stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for XNCR is 34.68 USD with a low forecast of 20.2 USD and a high forecast of 61.95 USD.

Lowest
Price Target
20.2 USD
19% Downside
Average
Price Target
34.68 USD
39% Upside
Highest
Price Target
61.95 USD
148% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for XNCR?

Click here to dive deeper.

Dividends

Xencor Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for XNCR is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

XNCR Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Xencor Inc Logo
Xencor Inc

Country

United States of America

Industry

Biotechnology

Market Cap

1.7B USD

Dividend Yield

0%

Description

Xencor, Inc. is biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. The company is headquartered in Monrovia California, California and currently employs 254 full-time employees. The company went IPO on 2013-12-03. The firm is advancing a portfolio of clinical-stage XmAb drug candidates from its protein engineering technology platforms. The firm uses its engineering capabilities to enable its understanding of protein structure and interactions to design technologies and XmAb development candidates with properties. The company is focused on the Fc domain, which is the part of an antibody that interacts with various segments of the immune system and controls antibody structure. The Fc domain is constant and interchangeable among antibodies, and its engineered Fc domains are the XmAb technology, which can be readily substituted for natural Fc domains. Its drug candidates include Plamotamab, XmAb717, Tidutamab, XmAb841, XmAb306, AMG 509, XmAb819, XmAb104, XmAb564 and Novartis XmAb.

Contact

CALIFORNIA
Monrovia California
111 W Lemon Ave
+16263055900.0
www.xencor.com

IPO

2013-12-03

Employees

254

Officers

Co-Founder, CEO, President & Director
Dr. Bassil I. Dahiyat Ph.D.
Executive VP of Research & Chief Scientific Officer
Dr. John R. Desjarlais Ph.D.
Senior VP, General Counsel & Corporate Secretary
Ms. Celia E. Eckert J.D.
Executive VP & Chief Development Officer
Dr. Nancy Valente M.D.
Senior VP & CFO
Mr. Bart Jan Cornelissen
Associate Director and Head of Corporate Communications & Investor Relations
Mr. Charles Liles
Show More
Senior VIce President of Human Resources
Ms. Jennifer Sandoz
Senior Vice President of Business Development
Dr. Jeremy Grunstein Ph.D.
Senior Vice President of Regulatory Affairs & Quality Assurance
Mr. Kirk Rosemark RAC
Senior Vice President of Program Leadership & Alliance Management
Mr. Eric P. Kowack
Show Less

See Also

Discover More
What is the Intrinsic Value of one XNCR stock?

The intrinsic value of one XNCR stock under the Base Case scenario is 16.41 USD.

Is XNCR stock undervalued or overvalued?

Compared to the current market price of 25.01 USD, Xencor Inc is Overvalued by 34%.

Back to Top